THE LANCET Global Health

Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Jalali MS, DiGennaro C, Sridhar D. Transparency assessment of COVID-19 models. *Lancet Glob Health* 2020; published online Oct 27. http://dx.doi.org/10.1016/S2214-109X(20)30447-2.



Percent of COVID-19 models (n=29) which satisfy transparency assessment criteria

Fig. S1. Percent of COVID-19 models (n=29) which satisfy transparency assessment criteria

*Five regression models are exempt from this criterion, as there is no visualization that communicates model structure. **codes used for a generalized model are not sufficient; we were able to successfully retrieve the codes of each model that provided a retrieval method.

COVID-19 Model Transparency Assessment Criteria 2* 3 5* 6* 7 8* 9* 10* 11 12* 13* 14* 15 16 17 18 19 20* 21 22 23 24 25* 26* 27 28* 29* 1 4 Are the geography and population defined? Are the dates of the modeled period defined? Is the modeling method clearly denoted? Are the model mechanisms described? Is there a high-level visualization of the model?** Are model equations reported? Are modeling assumptions discussed? Are parameter values (known/assumed constants) reported? Are all data sources (longitudinal data) reported? Are all data (longitudinal) provided? Does the specified data retrieval method work? Are parameters clearly defined? Are data assumptions disclosed? Are potential biases of the data disclosed? Are any codes reported?*** Is there documentation for the codes? Is the software used identifiable? Is model calibration (parameter estimation) reported? Are estimated model parameters reported? Is quality of simulated data fit to historical data reported? Is model evaluation/testing (other than fit to data and sensitivity analysis) reported? Is any type of sensitivity/uncertainty analysis reported? Is sensitivity of outcomes to data uncertainty/assumptions reported? Is sensitivity of outcomes to model formulation assumptions reported? Is there discussion about research limitations? Are sources of funding disclosed? Are potential conflicts of interest disclosed?

Supplementary Table S1: Transparency Assessment of 29 COVID-19 models

*preprint; **n=24, there was no expectation of this for purely statistical models; ***we were also able to retrieve all codes using the specified method. green=yes; red=no; yellow=partially; gray=exempt (only applicable for the assessment of high-level model visualization)

Reviewed models:

1. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* 2020; **395**(10225): 689-97.

2. Branas CC, Rundle A, Pei S, et al. Flattening the curve before it flattens us: hospital critical care capacity limits and mortality from novel coronavirus (SARS-CoV2) cases in US counties. *medRxiv* 2020.

3. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature* 2020.

4. Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. *Science* 2020; **369**(6502): 413-22.

- 5. Ferguson N, Laydon D, Nedjati Gilani G, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. 2020.
- 6. Murray C. Forecasting the impact of the first wave of the COVID-19 pandemic on hospital demand and deaths for the USA and European Economic Area countries. 2020.
- 7. Chinazzi M, Davis JT, Ajelli M, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. *Science* 2020; **368**(6489): 395-400.
- 8. Osthus DDV, S. COVID-19 Confirmed and Forecasted Case Data. 2020. https://covid-19.bsvgateway.org/.
- 9. Bertsimas D. DELPHI Epidemiological Model Documentation. 2020.
- 10. Moss R, Wood J, Brown D, et al. Modelling the impact of COVID-19 in Australia to inform transmission reducing measures and health system preparedness. medRxiv 2020.
- 11. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 2020; 368(6490): 489-93.

12. Spencer Woody MT, Dahan M, Gaither K, Fox SJ, Meyers LA, Scott J. Projections for first-wave COVID-19 deaths across the US using social-distancing measures derived from mobile phones. 2020.

- 13. Gu Y. COVID-19 Projections Using Machine Learning. 2020. https://covid19-projections.com/.
- 14. España G. Forecasting COVID-19 mortality in the US midwest. 2020.
- 15. Kucharski AJ, Russell TW, Diamond C, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. The lancet infectious diseases 2020.
- 16. Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. The Lancet Global Health 2020.

17. Prem K, Liu Y, Russell TW, et al. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. *The Lancet Public Health* 2020.

- 18. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020; 368(6493): 860-8.
- 19. Roosa K, Lee Y, Luo R, et al. Real-time forecasts of the COVID-19 epidemic in China from February 5th to February 24th, 2020. Infectious Disease Modelling 2020; 5: 256-63.
- 20. Peng L, Yang W, Zhang D, Zhuge C, Hong L. Epidemic analysis of COVID-19 in China by dynamical modeling. arXiv preprint arXiv:200206563 2020.
- 21. Yang Z, Zeng Z, Wang K, et al. Modified SEIR and AI prediction of the epidemics trend of COVID-19 in China under public health interventions. *Journal of Thoracic Disease* 2020; **12**(3): 165.

22. Lin Q, Zhao S, Gao D, et al. A conceptual model for the outbreak of Coronavirus disease 2019 (COVID-19) in Wuhan, China with individual reaction and governmental action. *International journal of infectious diseases* 2020.

- 23. Fanelli D, Piazza F. Analysis and forecast of COVID-19 spreading in China, Italy and France. *Chaos, Solitons & Fractals* 2020; **134**: 109761.
- 24. Boldog P, Tekeli T, Vizi Z, Dénes A, Bartha FA, Röst G. Risk assessment of novel coronavirus COVID-19 outbreaks outside China. Journal of clinical medicine 2020; 9(2): 571.
- 25. Chang SL, Harding N, Zachreson C, Cliff OM, Prokopenko M. Modelling transmission and control of the COVID-19 pandemic in Australia. arXiv preprint arXiv:200310218 2020.
- 26. Shen M, Peng Z, Xiao Y, Zhang L. Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China. BioRxiv 2020.
- 27. Zhao S, Chen H. Modeling the epidemic dynamics and control of COVID-19 outbreak in China. Quantitative Biology 2020; 8(1): 11-9.

28. Davies NG, Kucharski AJ, Eggo RM, Gimma A, Edmunds WJ. The effect of non-pharmaceutical interventions on COVID-19 cases, deaths and demand for hospital services in the UK: a modelling study. *medRxiv* 2020: 2020.04.01.20049908.

29. Peak CM, Kahn R, Grad YH, et al. Comparative Impact of Individual Quarantine vs. Active Monitoring of Contacts for the Mitigation of COVID-19: a modelling study. *medRxiv* 2020: 2020.03.05.20031088.